Accredo (Evernorth Health Services)

Overview

Accredo is Evernorth Health Services’ specialty pharmacy platform inside The Cigna Group. It is strongest when a manufacturer needs specialty dispensing scale, payer/PBM connectivity through Express Scripts, disease-specific clinical support, and adjacent specialty distribution through CuraScript SD.

For a biopharma launch team, Accredo is not a neutral independent specialty pharmacy. It is a vertically integrated Evernorth option: valuable for access, benefits, data, rare-disease handling, field nursing, and high-volume specialty reach, but requiring careful diligence around payer steering, manufacturer data firewalling, and whether PBM ownership creates channel conflict for the brand.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Accredo (Evernorth Health Services) is evaluated as vertically integrated Evernorth option: valuable for access, benefits, data, rare-disease handling, field nursing, and high-volume specialty reach, but requiring careful diligence around payer steering, manufacturer data firewalling, and whether PBM ownership creates channel conflict for the brand.

Capability	Buyer should compare	Accredo (Evernorth Health Services) readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Core fulfillment handoff. Accredo brings national specialty pharmacy scale with Express Scripts / Evernorth payer connectivity. Best fit when channel access and payer integration matter as much as dispensing.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Core / diligence required. The Evernorth stack is built for benefit and access workflows, but manufacturers should validate brand-specific PA, affordability, foundation, and escalation designs.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Core engagement model. Accredo has 15 condition-specific TRCs and reports 500+ specialty-trained pharmacists and 600+ field nurses, plus social-work, dietitian, advocate, and physician-engagement support.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Core complex-product handling. Public Evernorth materials describe ultra-cold handling, clean-room infrastructure, IceGen packaging optimization, and rare-disease / gene-therapy distribution experience.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Strong but needs contracting detail. Pharma Hub Portal and MyAccredoPatients.com add status visibility; RFPs should define data feeds, firewalling, reporting rights, and how portal views map to manufacturer dashboards.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Core site-of-care coordination. CuraScript SD adds provider-administered distribution, Accredo uses field nurses for home administration when appropriate, and Evernorth has health-system exposure through CarePathRx and Shields activity.

Buyer Fit

• Launch-team fit: Include Accredo when the product needs large-network specialty access, Evernorth / Express Scripts connectivity, payer-data-enabled patient identification, rare disease or CGT handling, digital workflow visibility, or a single ecosystem spanning dispensing and specialty distribution.
• Therapy and product fit: Strongest public signals are oncology, rare disease, immunology / inflammatory disease, neurology, hematology, pulmonary, transplant, fertility, immunoglobulin, and cell / gene therapy.
• Commercial fit: Pricing is undisclosed, so assume an RFP-led scope with SLAs, data feeds, launch timing, adherence services, patient-support responsibilities, and governance defined in the agreement.
• Where it may not fit: Manufacturers that prioritize independence from PBM-owned channels, a very small rare-disease white-glove model, or distributor-neutral health-system strategy should compare Accredo against independent rare-disease SPs and health-system SP partners.
• Contracting diligence: Confirm limited-distribution eligibility, payer steering rules, data firewalling with Express Scripts / Cigna, hub handoffs, REMS scope, state-by-state onboarding, Pharma Hub Portal access, and whether CuraScript SD or health-system investments create the right site-of-care path for the product.

Differentiators

• 15 TRCs with pharmacy and nursing depth: The TRC model gives Accredo disease-state care teams rather than a purely transactional dispensing model; Accredo reports 500+ specialty-trained pharmacists and 600+ field nurses.
• Evernorth / Express Scripts integration: Accredo can connect specialty pharmacy execution to PBM, benefit, payer-data, and affordability workflows that independent SPs cannot replicate at the same scale.
• Rare disease and cell / gene support: Evernorth company materials describe Luxturna access, rare-disease TRC support, field nurses across all 50 states, Therapy Link, CuraScript SD distribution, and payer-protection tools.
• Digital workflow visibility: Pharma Hub Portal, MyAccredoPatients.com, Accredo One Adherence, and digital financial navigation give manufacturers and prescribers more visibility into initiation, adherence, and affordability handoffs.
• Cold-chain and complex handling: IceGen packaging optimization, ultra-cold storage, clean-room infrastructure, and complex delivery routing are central to the rare-disease / CGT proposition.
• CuraScript SD adjacency: Accredo can sit beside provider-administered specialty distribution, giving manufacturers a path across patient-direct and buy-and-bill use cases.

RFP Questions

• Which payer, LDD, and health-system channels can Accredo actually access for this product, and how much volume is expected to come through Evernorth / Express Scripts routing?
• What clinical protocol, pharmacist touch cadence, nursing support, social-work support, and escalation model will be therapy-specific rather than generic?
• How will manufacturer data be separated from Express Scripts / Cigna payer economics, and what firewall commitments are contractually enforceable?
• How frequently will dispense, abandonment, refill, affordability, prior-authorization, and adherence data be delivered to the manufacturer?
• Which Pharma Hub Portal, MyAccredoPatients.com, Accredo One Adherence, and financial-navigation views are included for the manufacturer, provider, and patient?
• Which cold-chain, REMS, infusion, ultra-cold, clean-room, or controlled-substance requirements are handled internally versus through CuraScript SD or other partners?
• What state-by-state onboarding constraints, licensure issues, or communication rules could affect speed to therapy?
• For rare disease or CGT, which named team will own genetic-testing evidence, patient identification, affordability routing, site-of-care coordination, and missed-dose escalation?

Recent Activity

• May 2026 - Current Accredo site refresh: Current Accredo pages emphasize 500+ specialty-trained pharmacists, 600+ field nurses, 15 TRCs, Pharma Hub Portal visibility, MyAccredoPatients.com workflows, Accredo One Adherence, and digital financial navigation.
• February 2026 - CarePathRx acquisition closed: Evernorth completed its acquisition of hospital pharmacy specialist CarePathRx, expanding health-system pharmacy exposure alongside Accredo and CuraScript SD.
• February 2026 - Express Scripts consent order: Express Scripts entered a consent order requiring spread-pricing and formulary-transparency changes, a reminder that PBM-owned specialty pharmacy economics remain under regulatory pressure.
• January 2026 - Accredo / Cigna lawsuit: Plaintiffs filed a putative antitrust class action against Accredo, Express Scripts, and Cigna alleging delays in specialty prescriptions; the case remains a public operational and reputational diligence item.
• 2025 - Shields Health Solutions investment: Evernorth announced a major preferred-equity investment in Shields Health Solutions, adding health-system specialty pharmacy exposure outside Accredo’s core PBM-owned model.
• 2025 - Therapy Link launch materials: Evernorth described Therapy Link as a gene / cell therapy support model that combines patient identification, payer protection, specialty distribution, and Accredo clinical support.
• 2025 - Newark Delaware facility: Evernorth expanded Accredo and CuraScript SD operations in Delaware, co-locating specialty pharmacy and specialty distribution infrastructure.